vs
Amphastar Pharmaceuticals, Inc.（AMPH）与Walker & Dunlop, Inc.（WD）财务数据对比。点击上方公司名可切换其他公司
Walker & Dunlop, Inc.的季度营收约是Amphastar Pharmaceuticals, Inc.的1.9倍（$340.0M vs $183.1M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs -12.9%，领先26.2%），Walker & Dunlop, Inc.同比增速更快（-0.4% vs -1.8%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $-680.1M），过去两年Walker & Dunlop, Inc.的营收复合增速更高（22.1% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
Walker & Dunlop, Inc.是美国乃至全球规模领先的商业地产金融与咨询服务机构，为客户提供覆盖商业地产领域的多元金融解决方案及专业咨询服务，业务辐射全球多个市场，在行业内拥有深厚的资源积累与广泛的市场认可度。
AMPH vs WD — 直观对比
营收规模更大
WD
是对方的1.9倍
$183.1M
营收增速更快
WD
高出1.4%
-1.8%
净利率更高
AMPH
高出26.2%
-12.9%
自由现金流更多
AMPH
多$704.7M
$-680.1M
两年增速更快
WD
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $340.0M |
| 净利润 | $24.4M | $-13.9M |
| 毛利率 | 46.8% | — |
| 营业利润率 | 19.4% | -17.2% |
| 净利率 | 13.3% | -12.9% |
| 营收同比 | -1.8% | -0.4% |
| 净利润同比 | -35.7% | -131.0% |
| 每股收益（稀释后） | $0.51 | $-0.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHWD
| Q4 25 | $183.1M | $340.0M | ||
| Q3 25 | $191.8M | $337.7M | ||
| Q2 25 | $174.4M | $319.2M | ||
| Q1 25 | $170.5M | $237.4M | ||
| Q4 24 | $186.5M | $341.5M | ||
| Q3 24 | $191.2M | $292.3M | ||
| Q2 24 | $182.4M | $270.7M | ||
| Q1 24 | $171.8M | $228.1M |
净利润AMPHWD
| Q4 25 | $24.4M | $-13.9M | ||
| Q3 25 | $17.4M | $33.5M | ||
| Q2 25 | $31.0M | $34.0M | ||
| Q1 25 | $25.3M | $2.8M | ||
| Q4 24 | $38.0M | $44.8M | ||
| Q3 24 | $40.4M | $28.8M | ||
| Q2 24 | $37.9M | $22.7M | ||
| Q1 24 | $43.2M | $11.9M |
毛利率AMPHWD
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
营业利润率AMPHWD
| Q4 25 | 19.4% | -17.2% | ||
| Q3 25 | 13.2% | 13.6% | ||
| Q2 25 | 24.2% | 14.5% | ||
| Q1 25 | 21.9% | 2.2% | ||
| Q4 24 | 24.2% | 15.3% | ||
| Q3 24 | 29.8% | 12.8% | ||
| Q2 24 | 30.3% | 10.4% | ||
| Q1 24 | 27.9% | 6.0% |
净利率AMPHWD
| Q4 25 | 13.3% | -12.9% | ||
| Q3 25 | 9.0% | 9.9% | ||
| Q2 25 | 17.8% | 10.6% | ||
| Q1 25 | 14.8% | 1.2% | ||
| Q4 24 | 20.4% | 13.1% | ||
| Q3 24 | 21.1% | 9.9% | ||
| Q2 24 | 20.8% | 8.4% | ||
| Q1 24 | 25.1% | 5.2% |
每股收益（稀释后）AMPHWD
| Q4 25 | $0.51 | $-0.41 | ||
| Q3 25 | $0.37 | $0.98 | ||
| Q2 25 | $0.64 | $0.99 | ||
| Q1 25 | $0.51 | $0.08 | ||
| Q4 24 | $0.74 | $1.32 | ||
| Q3 24 | $0.78 | $0.85 | ||
| Q2 24 | $0.73 | $0.67 | ||
| Q1 24 | $0.81 | $0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $299.3M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $1.7B |
| 总资产 | $1.6B | $5.1B |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHWD
| Q4 25 | $282.8M | $299.3M | ||
| Q3 25 | $276.2M | $274.8M | ||
| Q2 25 | $231.8M | $233.7M | ||
| Q1 25 | $236.9M | $181.0M | ||
| Q4 24 | $221.6M | $279.3M | ||
| Q3 24 | $250.5M | $179.8M | ||
| Q2 24 | $217.8M | $208.1M | ||
| Q1 24 | $289.6M | $216.5M |
总债务AMPHWD
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHWD
| Q4 25 | $788.8M | $1.7B | ||
| Q3 25 | $776.7M | $1.8B | ||
| Q2 25 | $757.5M | $1.8B | ||
| Q1 25 | $751.3M | $1.7B | ||
| Q4 24 | $732.3M | $1.7B | ||
| Q3 24 | $727.7M | $1.7B | ||
| Q2 24 | $713.3M | $1.7B | ||
| Q1 24 | $672.4M | $1.7B |
总资产AMPHWD
| Q4 25 | $1.6B | $5.1B | ||
| Q3 25 | $1.7B | $5.8B | ||
| Q2 25 | $1.6B | $4.7B | ||
| Q1 25 | $1.6B | $4.5B | ||
| Q4 24 | $1.6B | $4.4B | ||
| Q3 24 | $1.5B | $4.6B | ||
| Q2 24 | $1.5B | $4.2B | ||
| Q1 24 | $1.6B | $3.8B |
负债/权益比AMPHWD
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $-664.3M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $-680.1M |
| 自由现金流率自由现金流/营收 | 13.4% | -200.0% |
| 资本支出强度资本支出/营收 | 4.5% | 4.6% |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | $-2.2B |
8季度趋势，按日历期对齐
经营现金流AMPHWD
| Q4 25 | $32.9M | $-664.3M | ||
| Q3 25 | $52.6M | $-948.1M | ||
| Q2 25 | $35.6M | $-238.5M | ||
| Q1 25 | $35.1M | $-281.1M | ||
| Q4 24 | $29.0M | $129.4M | ||
| Q3 24 | $60.0M | $-202.0M | ||
| Q2 24 | $69.1M | $-237.8M | ||
| Q1 24 | $55.3M | $38.4M |
自由现金流AMPHWD
| Q4 25 | $24.6M | $-680.1M | ||
| Q3 25 | $47.2M | $-950.4M | ||
| Q2 25 | $25.0M | $-241.0M | ||
| Q1 25 | $24.4M | $-284.7M | ||
| Q4 24 | $16.6M | $116.4M | ||
| Q3 24 | $46.2M | $-204.0M | ||
| Q2 24 | $63.1M | $-241.7M | ||
| Q1 24 | $46.5M | $35.2M |
自由现金流率AMPHWD
| Q4 25 | 13.4% | -200.0% | ||
| Q3 25 | 24.6% | -281.5% | ||
| Q2 25 | 14.3% | -75.5% | ||
| Q1 25 | 14.3% | -120.0% | ||
| Q4 24 | 8.9% | 34.1% | ||
| Q3 24 | 24.1% | -69.8% | ||
| Q2 24 | 34.6% | -89.3% | ||
| Q1 24 | 27.1% | 15.4% |
资本支出强度AMPHWD
| Q4 25 | 4.5% | 4.6% | ||
| Q3 25 | 2.8% | 0.7% | ||
| Q2 25 | 6.1% | 0.8% | ||
| Q1 25 | 6.3% | 1.5% | ||
| Q4 24 | 6.7% | 3.8% | ||
| Q3 24 | 7.2% | 0.7% | ||
| Q2 24 | 3.3% | 1.4% | ||
| Q1 24 | 5.1% | 1.4% |
现金转化率AMPHWD
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | -28.34× | ||
| Q2 25 | 1.15× | -7.02× | ||
| Q1 25 | 1.39× | -102.07× | ||
| Q4 24 | 0.76× | 2.89× | ||
| Q3 24 | 1.48× | -7.01× | ||
| Q2 24 | 1.82× | -10.49× | ||
| Q1 24 | 1.28× | 3.24× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
WD
暂无分部数据
